Recent progress on tyrosine kinase 2 JH2 inhibitors

被引：7
|
作者：
Deng, Lidan [1 ]
Wan, Li [1 ]
Liao, Tingting [2 ]
Wang, Lin [3 ]
Wang, Jie [4 ]
Wu, Xianbo [1 ]
Shi, Jianyou [1 ,5 ,6 ,7 ]
机构：
[1] Chengdu Sport Univ, Sch Sports Med & Hlth, Chengdu 610041, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China
[3] Xihua Univ, Coll Food & Bioengn, Chengdu 610039, Peoples R China
[4] Guizhou Univ Tradit Chinese Med, Guiyang 550002, Guizhou, Peoples R China
[5] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Pharm,Sch Med, Personalized Drug Therapy Key Lab Sichuan Prov, Chengdu 610072, Sichuan, Peoples R China
[6] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China
[7] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China
来源：
INTERNATIONAL IMMUNOPHARMACOLOGY | 2023年 / 121卷
基金：
中国国家自然科学基金;
关键词：
Tyrosine kinase 2 (TYK2); JH2; inhibitor; Autoimmune diseases; Deucravacitinib; BMS-986202; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PSORIATIC-ARTHRITIS; CLINICAL-FEATURES; JAK INHIBITORS; JANUS KINASES; IMMUNE; MECHANISMS; DISCOVERY; STATS; EPIDEMIOLOGY;
D O I：
10.1016/j.intimp.2023.110434
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family, which can regulate the signaling of multiple pro-inflammatory cytokines, including IL12, IL23 and type I interferon (IFN & alpha;/& beta;), and its inhibitors can treat autoimmune diseases caused by the abnormal expression of IL12 and IL23. Interest in TYK2 JH2 inhibitors has increased as a result of safety concerns with JAK inhibitors. This overview introduces TYK2 JH2 inhibitors that are already on the market, including Deucravactinib (BMS-986165), as well as those currently in clinical trials, such as BMS-986202, NDI-034858, and ESK-001.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis
    Liu, Qi
    Xia, Yuan
    Liu, Lin
    Zhou, Yuan
    Li, Yumei
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (10) : 1001 - 1007
  • [2] Covalent Modification of the JH2 Domain of Janus Kinase 2
    Henry, Sean P.
    Liosi, Maria-Elena
    Ippolito, Joseph A.
    Menges, Fabian
    Newton, Ana S.
    Schlessinger, Joseph
    Jorgensen, William L.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (11): : 1819 - 1826
  • [3] Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)
    Min, Xiaoshan
    Ungureanu, Daniela
    Maxwell, Sarah
    Hammaren, Henrik
    Thibault, Steve
    Hillert, Ellin-Kristina
    Ayres, Merrill
    Greenfield, Brad
    Eksterowicz, John
    Gabel, Chris
    Walker, Nigel
    Silvennoinen, Olli
    Wang, Zhulun
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (45) : 27261 - 27270
  • [4] Tyrosine kinase 2 inhibitors in autoimmune diseases
    Ramakrishna, Chethana
    Mason, Alice
    Edwards, Christopher J.
    AUTOIMMUNITY REVIEWS, 2024, 23 (11)
  • [5] Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors
    Martin, George
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 417 - 435
  • [6] Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
    Nikolopoulos, Dionysis
    Parodis, Ioannis
    FRONTIERS IN MEDICINE, 2023, 10
  • [7] Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
    Chimalakonda, Anjaneya
    Burke, James
    Cheng, Lihong
    Catlett, Ian
    Tagen, Michael
    Zhao, Qihong
    Patel, Aditya
    Shen, Jun
    Girgis, Ihab G.
    Banerjee, Subhashis
    Throup, John
    DERMATOLOGY AND THERAPY, 2021, 11 (05) : 1763 - 1776
  • [8] The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors
    Baskin, R.
    Majumder, A.
    Sayeski, P. P.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4551 - 4558
  • [9] Establishing the role of tyrosine kinase 2 in cancer
    Uebel, Caroline
    Mousset, Stephanie
    Trufa, Denis
    Sirbu, Horia
    Finotto, Susetta
    ONCOIMMUNOLOGY, 2013, 2 (01):
  • [10] Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors
    Wang, Yazhou
    Huang, Wei
    Xin, Minhang
    Chen, Pan
    Gui, Li
    Zhao, Xinge
    Tang, Feng
    Wang, Jia
    Liu, Fei
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (01) : 75 - 83
12345